Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 4, 2003, Pages 956-963

  Zelefsky, Michael J ^a   Yamada, Yoshiya ^a   Marion, Christine ^a   Sim, Sang ^a   Cohen, Gilad ^a   Ben Porat, Leah ^a   Silvern, David ^b   Zaider, Marco ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Brachytherapy; Intraoperative planning; Prostate cancer; Urinary toxicity

Indexed keywords

DOSIMETRY; GENETIC ALGORITHMS; PATIENT TREATMENT; PROSTHETICS; TUMORS;

CONFORMAL TREATMENT;

TOXICITY;

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ACUTE TOXICITY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; GENETIC ALGORITHM; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RECTUM; TREATMENT OUTCOME; TREATMENT PLANNING; ULTRASOUND; URETHRA; URINE RETENTION;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; INTRAOPERATIVE PERIOD; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONEUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTAL DISEASES; ULTRASONOGRAPHY, INTERVENTIONAL; URETHRAL DISEASES;

EID: 0037443428     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)04142-1     Document Type: Article

References (34)

1. Ragde H., Korb L.J., Elgamal A.A., et al. Modern prostate brachytherapy Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 89:2000;135-141.
2. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;839-850.
3. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 47:2000;1261-1267.
4. Potters L., Cha C., Oshinsky G., et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 5:1999;301-306.
5. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
6. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients Results from a single practice. Int J Radiat Oncol Biol Phys. 48:2000;111-117.
7. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
8. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 21:1991;935-939.
9. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
10. Desai J., Stock R.G., Stone N.N., et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Invest. 6:1998;135-141.
11. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy A prospective study. Int J Radiat Oncol Biol Phys. 52:2002;712-719.
12. Lee N., Wu C., Brody R., et al. Factors predicting for post-implantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;1457-1460.
13. Crook J., Mclean M., Catton C., et al. Factors influencing risk of acute retention after TRUS-guided permanent seed implantation. Int J Radiat Oncol Biol Phys. 52:2002;453-460.
14. Thomas M.D., Cormack R., Tempany C.M., et al. Identifying the predictors of acute urinary retention following magnetic resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;905-908.
15. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 53:2002;91-98.
16. Talcott J.A., Clark J.A., Stark P.C., et al. Long-term treatment related complication of brachytherapy for early prostate cancer A survey of patients previously treated. J Urol. 166:2001;494-499.
17. Wei J.T., Dunn R.L., Sandler H.M., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 20:2002;557-566.
18. Zelefsky M.J., Yamada Y., Cohen G., et al. Postimplantation dosimetric analysis of permanent transperineal prostate implantation Improved dose distributions with an intraoperative computer-optimized conformal planning technique. Int J Radiat Oncol Biol Phys. 48:2000;601-608.
19. Yang G., Reinstein L.E., Pai Xu. A new genetic algorithm technique in optimization of permanent I-125 prostate implants. Med Phys. 25:1998;2308-2315.
20. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources Recommendations of the AAPM Radiation Committee Task Group No. 43. Med Phys. 22:1995;209-234.
21. Nag S., Beyer D., Freidland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 44:1999;789-799.
22. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
23. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
24. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1958;718-748.
25. Cox D.R. Regression models and life tables. J Roy Stat Soc. 34:1972;187-220.
26. Bice W.S. Jr, Prestidge B.R., Grimm P.D., et al. Centralized multi-institutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 41:1998;921-927.
27. Merrick G.S., Butler W.M., Dorsey A.T., et al. Potential role of various dosimetric quality indicators in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 44:1999;717-724.
28. Stock R.G., Stone N.N., Lo Y.C. Intraoperative dosimetric representation of the real-time ultrasound implant. Tech Urol. 6:2000;95-98.
29. Messing E.M., Zhang J.B., Rubens D.J., et al. Intraoperative optimized inverse planning for prostate brachytherapy Early experience. Int J Radiat Oncol Biol Phys. 44:1999;801-808.
30. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 85:1999;2460-2468.
31. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;3-11.
32. D'Amico A.V., Cormack P., Tempany C.M., et al. Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 42:1998;507-515.
33. Zelefsky M.J., Cohen G., Zakian K.L., et al. Intraoperative conformal optimization for transperineal prostate implantation using MR spectroscopic imaging. Cancer J Sci Am. 6:2000;249-255.
34. Dibiase S.J., Hosseinzadeh K., Gullapalli R.P., et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 52:2002;429-438.